Triastek and BioNTech enter pharmaceutical licensing agreement

Triastek, a leader in 3D printing pharmaceuticals, has entered into a research collaboration and platform technology license agreement with BioNTech, a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Under the agreement, the companies will develop RNA therapeutics for oral delivery based on 3D printing technology. The collaboration aims to provide groundbreaking therapies to address unmet medical needs in an easy-to-administer oral formulation.

Triastek will contribute its expertise in innovative oral tablet designs made possible by 3D printing – aimed at optimizing the delivery of RNA therapeutics across the gastrointestinal mucosa, minimizing degradation in the gastrointestinal tract, and delivering RNA therapeutics to the portion of the gastrointestinal tract where absorption will potentially be the greatest. Triastek will leverage its ability to create tablet structures with unique external and internal tablet geometries, including multiple-layer and multi-compartment designs – aiming to optimize the delivery of novel RNA therapeutics.

“We are immensely honored to announce our collaboration with BioNTech, a leader in revolutionizing patient care with transformative medicines,” said Dr. Senping Cheng, Founder and CEO of Triastek. “We believe this collaboration stands as a promising milestone in advancing oral RNA therapeutics using 3D printing technology and aims to set new benchmarks in the development of large molecule oral drugs. We are committed to working diligently together to make breakthroughs in oral delivery of RNA therapeutics.”

Under the terms of the agreement, Triastek will receive an upfront payment of $10 million, and will be eligible to receive development, regulatory, and commercial milestone payments potentially totaling over $1.2 billion, as well as tiered royalties on potential future product sales.